Form 4: Guardant Health Executive Chris Freeman Reports Stock Transactions

Guardant Health's Chief Commercial Officer, Chris Freeman, reported the acquisition of 1,402 shares and the disposal of 597 shares to cover tax obligations related to vesting restricted stock units.

Summary

• Chris Freeman, Chief Commercial Officer of Guardant Health, reported transactions involving the company's stock on December 15, 2024.
• Freeman acquired 1,402 shares of common stock through the vesting of restricted stock units.
• He also disposed of 597 shares to cover tax withholding obligations related to the vesting of these units.
• The disposal of shares was at a price of $34.76 per share.
• Following these transactions, Freeman beneficially owns 32,257 shares of Guardant Health common stock and 8,411 restricted stock units.

Sentiment

Score: 6

Explanation: The document reflects routine stock transactions related to executive compensation. It is neither particularly positive nor negative.

Positives

• The vesting of restricted stock units indicates a positive incentive structure for company executives.
• The acquisition of shares increases the executive's stake in the company.

Negatives

• The disposal of shares, while for tax purposes, reduces the executive's direct shareholding.

Risks

• There are no significant risks identified in this document.
• The transactions are routine and related to compensation.

Future Outlook

The remaining 67% of the restricted stock units will vest in equal quarterly installments over the next two years.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives trade company stock. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Similar stock transactions are common among executives in publicly traded companies, particularly in the biotech and healthcare sectors.
• Companies like Exact Sciences and Illumina also have executives who regularly report similar transactions related to stock options and restricted stock units.
• The vesting schedule of the restricted stock units is typical for executive compensation packages.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation.
• The transactions do not have a significant impact on employees, customers, suppliers, or creditors.

Next Steps

• The remaining restricted stock units will continue to vest quarterly over the next two years.

Key Dates

Keywords

Guardant Health, Chris Freeman, stock transaction, restricted stock units, SEC Form 4, executive compensation, insider trading